摘要
In April,the Hurun Research Institute released the Hurun China 100 Most Valuable Non-State-Controlled Healthcare Companies 2020,which showed that the drug company Hengrui Medicine as heading up the list with a valuation of USD 53.1bn.Th e average value of the Top 100 was USD 6.5bn,with the cut-off to make the list being USD 2.1bn.Rupert Hoogewerf,Chairman and Chief Researcher of the Hurun Report,said:“Coronavirus has thrown the spotlight onto China’s top healthcare companies.Six companies from the Hurun Top 100 saw their share price up by half between January 20 and February 28,led by the medical product business Allmed,which doubled in value,and followed by respiration equipment provider Yuyue,which rose by 62%.we should expect to see some of these companies continue to grow as the virus spreads around the world.”
